Moreover, the 36-month beta value for BGLC is 1.93.
The public float for BGLC is 7.07M and currently, short sellers hold a 0.61% of that float. On April 19, 2024, BGLC’s average trading volume was 1.49M shares.
BGLC) stock’s latest price update
The stock of BioNexus Gene Lab Corp (NASDAQ: BGLC) has increased by 34.00 when compared to last closing price of 0.63. Despite this, the company has experienced a 26.85% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-02-13 that BioNexus (NASDAQ: BGLC ) stock is rocketing higher on Tuesday despite a lack of news concerning the chemical raw material products company. Instead, traders are seeing shares of BGLC stock rally this morning alongside heavy trading.
BGLC’s Market Performance
BioNexus Gene Lab Corp (BGLC) has experienced a 26.85% rise in stock performance for the past week, with a 17.03% rise in the past month, and a 82.53% rise in the past quarter. The volatility ratio for the week is 22.36%, and the volatility levels for the past 30 days are at 12.55% for BGLC. The simple moving average for the last 20 days is 27.52% for BGLC stock, with a simple moving average of -36.85% for the last 200 days.
BGLC Trading at 17.19% from the 50-Day Moving Average
After a stumble in the market that brought BGLC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.25% of loss for the given period.
Volatility was left at 12.55%, however, over the last 30 days, the volatility rate increased by 22.36%, as shares surge +7.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +95.40% upper at present.
During the last 5 trading sessions, BGLC rose by +27.06%, which changed the moving average for the period of 200-days by -79.70% in comparison to the 20-day moving average, which settled at $0.6683. In addition, BioNexus Gene Lab Corp saw 60.11% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for BGLC
Current profitability levels for the company are sitting at:
- -0.29 for the present operating margin
- 0.14 for the gross margin
The net margin for BioNexus Gene Lab Corp stands at -0.3. The total capital return value is set at -0.3. Equity return is now at value -32.21, with -26.11 for asset returns.
Based on BioNexus Gene Lab Corp (BGLC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -4.07. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -204.92.
Currently, EBITDA for the company is -2.59 million with net debt to EBITDA at 2.09. When we switch over and look at the enterprise to sales, we see a ratio of 0.88. The receivables turnover for the company is 10.18for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To wrap up, the performance of BioNexus Gene Lab Corp (BGLC) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
